Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2024-12-19 Share Issue/Capital Cha…
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Cleansing Notice 2 pages 210.0KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 20 December 2024 regarding the issuance of 282,520 fully paid ordinary shares under an employee share plan. It includes a cleansing notice pursuant to Section 708A(5)(e) of the Corporations Act 2001, which is a regulatory compliance statement related to the issuance of shares without disclosure. The document does not contain financial statements, management discussion, or detailed financial data. It is a formal announcement about a share issue and related regulatory notice, not a full financial report or detailed capital update. Given the nature of the content—announcement of share issuance and compliance notice under the Corporations Act—it fits best under the category of Share Issue/Capital Change (SHA). The document length is under 5,000 characters and is a direct announcement, not a report publication or certification. Therefore, the classification is SHA with high confidence.
2024-12-19 English
4DMedical wins contract with University of Chicago Medicine 3 pages 200.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 16 December 2024, detailing a new commercial contract between 4DMedical and University of Chicago Medicine, as well as an expansion of a contract with UCSD Health. The content focuses on business development, partnership, and contract details rather than financial results, regulatory filings, or management changes. There are no financial statements, earnings data, or regulatory compliance information. The document is a corporate announcement about a commercial contract win and expansion, which fits the category of Capital/Financing Update (CAP) as it relates to company fundraising or financing activities through commercial contracts. The document length is 7813 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the best classification is Capital/Financing Update (CAP).
2024-12-15 English
4DMedical unveils CT VQ at RSNA 2024 3 pages 307.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 4 December 2024 from 4DMedical Limited. It details the unveiling of a new product, CT:VQ, at the RSNA 2024 conference, including clinical trial results and product features. The text is a corporate announcement focusing on product innovation, market opportunity, and upcoming FDA submission plans. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The document is not a full report but a press release-type announcement about a product launch and clinical presentation. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific categories such as Annual Report, Earnings Release, or Investor Presentation. The document length is 7894 characters, which is substantial but the content is clearly an announcement rather than a detailed report or transcript.
2024-12-03 English
4DMedical signs contract to expand in Western Australia 2 pages 228.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 2 December 2024, describing a commercial contract signed by 4DMedical with Perth Radiological Clinic to expand deployment of its technology. The content focuses on business development, partnership details, and future growth prospects. There are no financial statements, earnings data, regulatory certifications, or detailed financial analysis present. The document is a corporate announcement about a contract and business expansion, not a financial report or regulatory filing. It is longer than 5,000 characters and contains substantive information about the contract and company strategy. This fits best under Capital/Financing Update (CAP) as it relates to business growth and commercial contracts impacting company operations and potential revenue streams.
2024-12-01 English
Application for quotation of securities - 4DX 9 pages 22.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement related to the application for quotation of securities issued under an employee incentive scheme. It details the number and type of securities to be quoted, issue dates, and compliance with ASX Listing Rules. There is no financial performance data, management discussion, or report content. The document is a formal regulatory announcement about securities quotation, not a financial report or earnings release. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2024-11-28 English
4DMedical wins commercial contract with IPOC 2 pages 229.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 25 November 2024 about 4DMedical signing a commercial contract with a U.S.-based radiology provider IPOC. It discusses the contract details, the technology involved, and the company's commercial progress. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a commercial contract and business development, not a financial report or regulatory filing. It fits best under Capital/Financing Update (CAP) as it relates to a commercial contract and business expansion.
2024-11-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.